Invesco Biotechnology & Genome ETF
PBE
69 hedge funds and large institutions have $52.3M invested in Invesco Biotechnology & Genome ETF in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
15% more funds holding
Funds holding: 60 → 69 (+9)
1.14% more ownership
Funds ownership: 21.02% → 22.16% (+1.1%)
5% less capital invested
Capital invested by funds: $55M → $52.3M (-$2.71M)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$2.11M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$398K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$316K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$230K |
| 5 |
BTS
BB&T Securities
Richmond,
Virginia
|
+$225K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.71M |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$544K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$522K |
| 4 |
Goldman Sachs
New York
|
-$256K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$226K |
PBE Hedge Fund Activity: Q4 2017 in Review
69 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2017, worth a combined $52.3M — down 4.9% from $55M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PBE positions and 4 closed out — a net gain of 9 holders — while 14 added to existing stakes and 16 trimmed.
The largest buyer was Virtu Financial, adding an estimated $2.11M. The largest seller was Bank of America, cutting an estimated $1.71M.
- 69 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2017, up from 60 in Q3 2017.
- Funds reported $52.3M of Invesco Biotechnology & Genome ETF stock for Q4 2017, down 4.9% quarter-over-quarter.
- 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2017 and 4 closed out, a net change of +9 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q4 2017 was Virtu Financial, an estimated $2.11M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q4 2017 was Bank of America, an estimated $1.71M sold.
Based on aggregated 13F filings for Q4 2017.